Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 1.00 |
| ▸ | ANPEP | P15144 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 0.99 |
| ▸ | NPC1 | O15118 | 1/20 | 0.99 |
| ▸ | RAB9A | P51151 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20393806 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583945 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL13170049 | 1.00 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768692-B1 | TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS | UNIV YALE (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20100029544-A1 | Composition | THE ROBERT GORDON UNIVERSITY (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20090269397-A1 | TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS | YALE UNIVERSITY | 2009-10-29 | — | — | US | disclosed |
| US-20090239789-A1 | METHODS OF TREATMENT WITH DRUG LOADED POLYMERIC MATERIALS | YALE UNIVERSITY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7550154-B2 | Methods of treatment with drug loaded polymeric materials | YALE UNIVERSITY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7534448-B2 | Methods of treatment with drug loaded polymeric materials | YALE UNIVERSITY (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534449-B2 | Targeted and high density drug loaded polymeric materials | YALE UNIVERSITY (US) | 2009-05-19 | — | — | US | disclosed |
| EP-2044132-A1 | COMPOSITION | The Robert Gordon University (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008007092-A1 | COMPOSITION | THE ROBERT GORDON UNIVERSITY (GB) | 2008-01-17 | — | — | WO | disclosed |
| US-20080014144-A1 | Methods of Treatment with Drug Loaded Polymeric Materials | YALE UNIVERSITY | 2008-01-17 | — | — | US | disclosed |
| EP-1768692-A2 | TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS | YALE UNIVERSITY (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006080951-A2 | TARGETED AND HIGH DENSITY DRUG LOADED POLYMERIC MATERIALS | YALE UNIVERSITY (US) | 2006-08-03 | — | — | WO | disclosed |
| US-20060002971-A1 | Methods of treatment with drug loaded polymeric materials | YALE UNIVERSITY | 2006-01-05 | — | — | US | disclosed |
| US-20060002852-A1 | Targeted and high density drug loaded polymeric materials | YALE UNIVERSITY | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029544-A1 | Composition | CETP, LIPA, PNPLA2 | NPEPPS 442/4885ANPEP 383/4885SMN1; SMN2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.